Neuventis

Neuventis Therapeutics is a biotechnology company focused on developing small molecule therapies for neurodegenerative and lysosomal storage diseases. The company's lead programs center on the activation of glucocerebrosidase (GBA1), an enzyme critical for lysosomal health that is frequently impaired in conditions like Parkinson's disease and Gaucher disease. By utilizing a proprietary platform to identify potent, brain-penetrant GBA1 activators, Neuventis aims to restore cellular homeostasis and slow disease progression. The leadership team comprises seasoned executives with extensive backgrounds in neuroscience drug development from major pharmaceutical and biotech firms. Currently in the pre-clinical stage, the company is advancing its candidates toward IND-enabling studies to address significant unmet needs in the neurology space.